



# National Guideline on Antimicrobial Consumption (AMC) Surveillance in Bangladesh



**Directorate General of Drug Administration**  
Mohakhali, Dhaka-1212  
Ministry of Health and Family Welfare, Bangladesh

# National Guideline on Antimicrobial Consumption (AMC) Surveillance in Bangladesh

Document No. NRA-AMR-G-01  
Version. 01  
Effective Date: November, 2022

**Approved by:** The Taskforce to monitor antimicrobial consumption and use surveillance in Bangladesh on 12 June, 2022

**Approved by:** Health Service Division,  
Ministry of Health and Family Welfare, Bangladesh.



**Directorate General of Drug Administration**  
Mohakhali, Dhaka-1212  
Ministry of Health and Family Welfare, Bangladesh

# Contributors

## Technical Contributors (Not According to the Seniority)

1. **Major General Mohammad Yousuf**, Director General, Directorate General of Drug Administration.
2. **Mr. Md. Salahuddin**, Director (cc), Directorate General of Drug Administration and National Focal of AMC surveillance in Bangladesh.
3. **Prof Mahmudur Rahman**, Epidemiologist and Former Director, IEDCR.
4. **Prof Md. Sayedur Rahman**, Chairman, Department of Pharmacology, BSMMU.
5. **Ms. S. M. Sabrina Yesmin**, Assistant Director, Directorate General of Drug Administration and Fleming Fellow- AMC/AMU surveillance and alternative National Focal of AMC surveillance in Bangladesh.
6. **Dr. Aninda Rahman**, Deputy Program Manager, AMC, Viral hepatitis and diarrhea control program, CDC, DGHS.
7. **Mr. A. T. M. Golam Kibria Khan**, Assistant Director, Directorate General of Drug Administration.
8. **Mr. Md. Razibul Habib**, Assistant Director, Directorate General of Drug Administration.
9. **Mr. Mohamed Ramzy Ismail**, Technical Officer, Essential Drugs and Medicines, WHO Bangladesh.
10. **Paritosh Chakma**, National Consultant- Essential Drugs and Medicines, WHO Bangladesh.
11. **Dr. Majda Attauabi**, Statens Serum Institut, Denmark.
12. **Dr. Anders Rhod Larsen**, Statens Serum Institut, Denmark.
13. **Ms. Umme Habiba**, National Consultant, AMR-DGDA, WHO Bangladesh.

## Administrative Contributor

**Mr. Md. Mostafizur Rahman**  
Director(cc)  
Directorate General of Drug Administration.

## Funded by

Flemming Fund Fellowship Program, Mott MacDonald.

## Design & Graphics

Ms. S. M. Shanzida Yeasmin, Dhaka, Bangladesh.

## Supported by





গণপ্রজাতন্ত্রী বাংলাদেশ সরকার  
স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়  
স্বাস্থ্য সেবা বিভাগ  
ঔষধ প্রশাসন-১ শাখা  
www.hsd.gov.bd



নম্বর: ৪৫.০০.০০০০.১৮২.২২.০০১.২২.২১৬

তারিখ: ২৪ কার্তিক ১৪২৯  
০৯ নভেম্বর ২০২২

#### প্রজ্ঞাপন

Antimicrobial Consumption Surveillance সুষ্ঠুভাবে সম্পাদনের লক্ষ্যে “National Guidelines on Antimicrobial Consumption (AMC) Surveillance in Bangladesh” শিরোনামে গাইডলাইনটি অনুমোদিত হয়েছে।

০২। যথাযথ কর্তৃপক্ষের অনুমোদনক্রমে গাইডলাইনটি এতদসঙ্গে প্রেরণ করা হলো।

সংযুক্তি: অনুমোদিত গাইডলাইন।

রাষ্ট্রপতির আদেশক্রমে,

৯-১১-২০২২

মোহাম্মদ মোস্তাফিজুর রহমান  
সহকারী সচিব (ঔষধ প্রশাসন-১)  
ফোন: ০২-৫৫১০০৪৪২ (অফিস)  
ইমেইল: drugad1@hsd.gov.bd

নম্বর: ৪৫.০০.০০০০.১৮২.২২.০০১.২২.২১৬/১(১১)

তারিখ: ২৪ কার্তিক ১৪২৯  
০৯ নভেম্বর ২০২২

বিতরণ: সদয় জ্ঞাতার্থে ও কার্যার্থে (জ্যেষ্ঠতার ক্রমানুসারে নয়):

- ১) মন্ত্রিপরিষদ সচিব, মন্ত্রিপরিষদ বিভাগ, বাংলাদেশ সচিবালয়, ঢাকা।
- ২) মহাপরিচালক, স্বাস্থ্য অধিদপ্তর, মহাখালী, ঢাকা।
- ৩) মহাপরিচালক, ঔষধ প্রশাসন অধিদপ্তর, মহাখালী, ঢাকা (গাইডলাইনের নির্দেশনা প্রতিপালনের বিষয়টি সংশ্লিষ্ট সকলকে অবহিত করার অনুরোধসহ)।
- ৪) সভাপতি, টার্কফোর্স টু মনিটর এন্টিমাইক্রোবিয়াল কনজামশন/ ইউজ ইন বাংলাদেশ।
- ৫) পরিচালক, রোগতত্ত্ব, রোগ নিয়ন্ত্রণ ও গবেষণা ইনস্টিটিউট (আইইডিসিআর), মহাখালী, ঢাকা।
- ৬) লাইন ডিরেক্টর (সিডিসি), স্বাস্থ্য অধিদপ্তর, মহাখালী, ঢাকা।
- ৭) মন্ত্রীর একান্ত সচিব, স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়, ঢাকা (মাননীয় মন্ত্রীর সদয় অবগতির জন্য)।
- ৮) উপপরিচালক, বাংলাদেশ ফরম ও প্রকাশনা অফিস, তেজগাঁও, ঢাকা-১২০৮ (বাংলাদেশ গেজেটের পরবর্তী সংখ্যায় গাইডলাইনটি প্রকাশের অনুরোধসহ)।
- ৯) সচিবের একান্ত সচিব, স্বাস্থ্য সেবা বিভাগ, ঢাকা (সচিব মহোদয়ের সদয় অবগতির জন্য)।
- ১০) সিস্টেম এনালিস্ট, স্বাস্থ্য ও পরিবার কল্যাণ মন্ত্রণালয়, ঢাকা (ওয়েব সাইটে প্রকাশের জন্য অনুরোধসহ)।
- ১১) অফিস নথি।



**Mr. Zahid Maleque MP**  
Honorable-Minister

Ministry of Health and Family Welfare,  
Government of the People's Republic  
of Bangladesh.

I am pleased to know that Honorable Prime Minister of the People's Republic of Bangladesh, Her Excellency Sheikh Hasina is the co-chair of One Health Global Leaders Group on Antimicrobial Resistance (AMR). Under the strong and visionary leadership of Honorable Prime Minister, Bangladesh had made significant progress in the health sector as reflected through achievement of MDG targets.

DGDA together with all other stakeholder is working with AMR to protect the health of the people of the country as well as to protect our future generation. To reduce AMR in the country, it is crucial to ensure rational use of antimicrobial drugs. As AMR becomes the global concern now a days so all related department and directorate are doing their best on it.


Antimicrobial Consumption (AMC) surveillance is one of the important tools to monitor the use of antimicrobial drugs. Directorate General of Drug Administration as the National Centre for Antimicrobial Consumption Surveillance in Bangladesh is conducting the AMC surveillance from 2016. These surveillance data is used to monitor the antimicrobial consumption pattern of Bangladesh that ensures the appropriate policy decisions for the betterment of public.

So, it is very important to develop guidelines on AMC surveillance in Bangladesh, so that the regulators and the stakeholders will be aware of the surveillance process and the importance of the AMC surveillance.

I am delighted to know that DGDA has developed the National Guideline on AMC surveillance in Bangladesh maintaining the national and international norms and standards.

I wish the best success of this initiatives and best wishes for all concerns bodies including the issue.

Joy Bangla Joy Bangabandhu  
Long live Bangladesh



**Zahid Maleque, MP**



**Dr. Md. Anwar Hossain Howlader**  
Secretary, Health Services Division

Ministry of Health and Family Welfare,  
Government of the People's Republic  
of Bangladesh.

The world is on the verge of sliding back to 'pre-antibiotic era' due to evolving resistance against life-saving antimicrobial drugs, with fundamental effect on individual and public health. AMR is a multi-dimensional problem involving different sectors, disciplines and stakeholders requiring a One Health comprehensive approach for containment. Honorable Prime Minister of the People's Republic of Bangladesh, Her Excellency Sheikh Hasina is the co-chair of One Health Global Leaders Group on Antimicrobial Resistance (AMR). Under the strong and visionary leadership of Honorable Prime Minister, Bangladesh had made significant progress in the health sector as reflected through achievement of MDG targets. WHO has declared that AMR is one of the top 10 global public health threats facing humanity.

As a National Center of Antimicrobial Consumption surveillance, The Directorate General of Drug Administration is contributing to strengthening the knowledge and evidence through surveillance and ultimately contributing to the policy decisions to optimize the use of antimicrobial medicines in the health system. Based on the established system of AMC surveillance in the context of Bangladesh following the WHO's global guidelines, DGDA has developed the Guidelines on Antimicrobial Consumption (AMC) Surveillance in Bangladesh. The guidelines will guide the relevant stakeholders and relevant officials in conducting the national AMC surveillance in Bangladesh. I hope that these AMC surveillance guidelines and the effort of DGDA in conducting AMC surveillance will contribute to the policy decisions in containing the AMR situation in Bangladesh.

A handwritten signature in black ink, appearing to read 'Anwar', with the date '22/3/2022' written below it.

**Dr. Md. Anwar Hossain Howlader**




**Major General Mohammad Yousuf**  
Director General

---

Directorate General of Drug Administration.

Directorate General of Drug Administration is the National Regulatory Authority of drugs in Bangladesh under the ministry of health and family welfare. As per the Drugs (Control) Ordinance, 1982 section 5 (1) “ No medicine of any kind shall be manufactured for sale or be imported, distributed or sold unless it is registered with the licensing authority.” So we are ensuring the quality, safety and efficacy of all medicines as well as the antimicrobials drugs registered in Bangladesh.

Antimicrobial Resistance (AMR) is a national as well as global health threat. As the National center for antimicrobial consumption surveillance in Bangladesh we are conducting the AMC surveillance every year from 2016. Surveillance is an essential tool to inform policies and infection prevention and control responses. This data is the National level surveillance data which helps to understand the antimicrobial consumption trend in Bangladesh. This data helps to take regulatory decisions to combat AMR in the country. To sustain this AMC surveillance we have developed the National Guideline on Antimicrobial Consumption Surveillance in Bangladesh, which will be very helpful for the officials of DGDA and the stakeholders to understand the AMC surveillance process.

  
Major General Mohammad Yousuf  
Director General,  
Directorate General of Drug Administration.

# Table of Content

---

<b>01.</b>	<b>Introduction</b>	.....	<b>01</b>
	Global Response		
	Bangladesh Context		
	Antimicrobial Consumption (AMC)		
	Surveillance National Action Plan		
<b>02.</b>	<b>AMC Surveillance in Context of Bangladesh</b>	.....	<b>05</b>
<b>03.</b>	<b>Methodology</b>	.....	<b>08</b>
<b>04.</b>	<b>Data Collection</b>	.....	<b>13</b>
<b>05.</b>	<b>Variables</b>	.....	<b>17</b>
<b>06.</b>	<b>Reporting metrics</b>	.....	<b>20</b>
<b>07.</b>	<b>Dissemination of data</b>	.....	<b>26</b>
<b>08.</b>	<b>Conclusion</b>	.....	<b>28</b>
<b>09.</b>	<b>Definition</b>	.....	<b>30</b>
<b>10.</b>	<b>Annexes</b>	.....	<b>37</b>





# Abbreviations

<b>AMC</b>	Antimicrobial Consumption.
<b>AMR</b>	Antimicrobial resistance.
<b>AMU</b>	Antimicrobial Use.
<b>ARC</b>	Antimicrobial Resistance Containment.
<b>ATC</b>	The Anatomical Therapeutic Chemical code
<b>AWaRe</b>	Access. Watch. Reserve.
<b>CDC</b>	Communicable Disease Control
<b>DDD</b>	Defined Daily Doses
<b>DGDA</b>	Directorate General of Drug Administration
<b>DGHS</b>	Directorate General of Health Services
<b>DID</b>	DDD per 1000 inhabitants per day
<b>DU75</b>	Drug Utilization 75
<b>FAO</b>	Food and Agriculture Organization
<b>GAP</b>	Global Action Plan
<b>GARP</b>	Global Antibiotic Resistance Partnership
<b>GLASS</b>	Global Antimicrobial Resistance and Use Surveillance System.
<b>MOHFW</b>	Ministry of Health and Family Welfare
<b>MPP</b>	Medicinal Product Package
<b>OIE</b>	World Organization for Animal Health
<b>SOP</b>	Standard Operating Procedure
<b>UN</b>	United Nations
<b>WHO</b>	World Health Organization.




# Introduction

# 1.0 Introduction

**A**ntimicrobial resistance (AMR) is a global health and development threat. It requires urgent multisectoral action in order to achieve the Sustainable Development Goals (SDGs). WHO has declared that AMR is one of the top 10 global public health threats facing humanity. 'Global burden of bacterial antimicrobial

resistance in 2019: a systematic analysis,' The Lancet, 2022 published that every year 1.27 million people died on AMR. From this study it was found that five regions including all four regions of sub-Saharan Africa and south Asia had all-age death rates associated with bacterial AMR higher than 75 per 100000.



**All- age rate of deaths attributable to and associated with bacterial antimicrobial resistance by GBD region, 2019**

Surveillance is an essential tool to inform policies and infection prevention and control responses. Surveillance and monitoring are widely acknowledged as critical components of the response to antimicrobial resistance (AMR) and are one of the five strategic priorities of the Global Action Plan (GAP) on AMR.

Through surveillance, countries can detect the emergence of AMR and collect the data on AMR prevalence and antimicrobial use (AMU) necessary to guide patient treatment, identify populations at risk, inform policy development and assess the impact of interventions.

### 1.1 Role of surveillance data on antimicrobial consumption

- Data on antimicrobial consumption provide an important basis for countries to better understand the patterns and amount of antimicrobials used at the national level, which can inform policies, regulations and interventions to optimize the use of antimicrobials.
- This surveillance shows the great variation in quantity and type of antimicrobials consumed between the included countries. While the observed variation may be due to the selection and coverage of data sources, it also reflects an actual difference in antimicrobial use.
- Findings from this report confirm the need to take action to ensure that antimicrobials are used appropriately, such as enforcing prescription-only policies and implementing antimicrobial stewardship programmes.
- Governments and the international community should also ensure equitable access to antimicrobials, for example through strengthening of regulatory frameworks, procurement and supply chains.
- The process of implementing national surveillance of antimicrobial consumption has prompted countries to review national regulations, procurement and supply chains of medicines as a starting point to strengthen overall pharmaceutical systems.
- Reporting and sharing data on antimicrobial consumption both nationally and internationally is an essential element of surveillance and provides important information in the global fight against antimicrobial resistance.

### 1.2 Global Response to Antimicrobial Resistance

The WHO global action plan on antimicrobial resistance (GAP) adopted in the World Health Assembly requested the all countries to formulate National Action Plan (NAP) on AMR according to the GAP and outlined the strategic objectives to be achieved (WHO, 2015). The researcher and policy makers around the globe considered this issue a major threat to humanity and therefore United Nations General Assembly acknowledged the importance of collective initiative to promote sensible use of antimicrobials (UN, 2016).

Irrational use of antimicrobials was identified long before and number of interventions attempted to improve their use. Though World Health Organization (WHO) has taken initiative

long before, very little progress has been achieved so far (WHO, 2001). In spite of scarcity of information on microbial sensitivity pattern, couple of studies have been carried out to explore the situation of Antimicrobial Resistance in Bangladesh as well as to identify the effective intervention (Rahman and Huda, 2014; Sultana and Rahman, 2017; GARP-BWG, 2018; Mahboob and Rahman, 2019). The Global Framework for Development & Stewardship to Combat AMR, developed by WHO, OIE and FAO, provided guidance for global and national strategies with a focus on the appropriate use of antimicrobials in the context of One Health (WHO, FAO and OIE, 2017).

## 1.2 Global Response to Antimicrobial Resistance

WHO updated its Model List of Essential Medicines in 2017 and grouped antibiotics into Access, Watch and Reserve (AWaRe) categories based on treatment profile and potential for development of resistance (WHO, 2017; Sharland et al., 2018).

The upgradation is expected to ensure availability of appropriate antimicrobials whenever needed and thereby increase appropriateness of prescribing. Rational use may in turn reduce the possibility of development of resistance and may help to conserve the last-resort antimicrobials at the time of actual need.

## 1.3 Bangladesh Context

Bangladesh has formulated the strategic document titled “National Strategy for Antimicrobial Resistance Containment in Bangladesh 2011-2016”, which outlines tiered

monitoring frameworks incorporating different important stakeholders from human and animal health sector (MoHFW, 2015[a]).

## 1.4 Road map of National Action Plan of ARC

The Ministry of Health and Family Welfare (MoHFW) also developed and endorsed a National Action Plan, which identified the key areas and specific activities to be undertaken (MoHFW, 2017[a]). Later on, a detail document titled “Road map of National Action Plan of ARC” was also formulated that clearly outlined the activities along with the responsible government players and their expected role (MoHFW, 2017[b]).

In the Roadmap, under the heading of “4.2. Monitor use of Antimicrobials”, the statement has been mentioned as “4.2.3.

Estimation of consumption of antimicrobials both in human and animal health sector”. The Directorate General of Drug Administration (DGDA) is the responsible authority for estimating the consumption of antimicrobials in both human and veterinary.

In recent National Strategy and National Action Plan for Antimicrobial Resistance Containment in Bangladesh (2021-2026) section 3.3.3 DGDA is responsible to establish a system for the national surveillance of antimicrobial consumption (AMC) in human health.

## 1.5 Formation of the Task Force to Monitor AMC/AMU Surveillance in Bangladesh

In 2017 Directorate General of Drug Administration formed the “Task Force to Monitor Antimicrobial Consumption in Bangladesh”. The main responsibilities of this Task Force was: Approval of the methodology to study antimicrobial consumption in Bangladesh with appropriate modification of the WHO Methodology.

A series of meeting has been conducted to develop the methodology to conduct AMC surveillance in Bangladesh. In 2021 Ministry of Health and Family Welfare reformed the “Task Force to Monitor Antimicrobial Consumption and Antimicrobial Use Surveillance in Bangladesh”.



# AMC Surveillance in Context of Bangladesh

## 2.0 AMC Surveillance in Context of Bangladesh

**B**ack in 2017, World Health Organization (WHO), Bangladesh Country Office initiated capacity building to collect antimicrobial consumption data according to the WHO methodology for surveillance of antimicrobial consumption. WHO provided training of two focal persons by WHO/HQ, training of a wider group of professionals at DGDA .

In 2017, during the pilot phase attempts were made to adopt the global methodology in accordance with the perspective or context of Bangladesh. That modification was placed and accepted by the Task Force to Monitor Antimicrobial Consumption in Bangladesh.

In order to implement these activities in a scientific way and to keep objectivity, WHO provided support to DGDA in collaboration with Bangabandhu Sheikh Mujib Medical University to establish a National Antimicrobial Monitoring System.

Since 2016, in Bangladesh, WHO, DGHS, DGDA, FAO, DG DLS and BSMMU are participating World Awareness Antibiotics Week in order to build awareness among the concerned people regarding issues related to AMR. In addition, civil society initiatives (Bangladesh

AMR Response Alliance (BARA), onlinesocial forum for medical profession ‘Platform’ and different professional organizations also organized and participated in number of awareness campaign and scientific seminars. These activities has attracted , immense interest among key persons of the Ministry of Health and Family Welfare (MoHFW) and Ministry of Livestock and Fisheries (MoLF).

In 2021 with the funding and technical support of Fleming Fund Fellowship, a SOP was developed to conduct the Antimicrobial Consumption Surveillance. With the help of mentorship from Statens Serum Institut, Denmark and Fleming Fund AMC/U surveillance Fellow conducted the Antimicrobial Consumption Surveillance for the year 2019 and 2020.

The Ministry of Health and Family Welfare nominated DGDA as the National Centre for AMC surveillance of Bangladesh and also nominated the National and alternate National focal for AMC surveillance reporting to WHO GLASS-AMC platform. As a continuation of these activities, this guideline for AMC surveillance in Bangladesh has been developed.

### 2.1 National center for Antimicrobial Consumption (AMC) Surveillance

Directorate General of Drug Administration (DGDA) will play the role as the National center for Antimicrobial Consumption (AMC) Surveillance in Bangladesh based on official nomination of Ministry of Health and Family Welfare (Annex-1). The nominated National focal and an alternate National Focal will coordinate the

overall surveillance activities including GLASS-AMC data reporting, the collaboration with World Health Organization and other relevant Developments partners as relevant. Ultimately the “AMR Cell” of DGDA will involve to conduct the Antimicrobial Consumption (AMC) Surveillance every year.

### 2.2 ToR of “Task Force to Monitor AMC/AMU Surveillance in Bangladesh”

1. Approval of the methodology to study antimicrobial consumption and antimicrobial use in Bangladesh with appropriate modification of the WHO/OIE Methodology.

2. Periodic review and approval of the National Antimicrobial Consumption and Antimicrobial Use survey activity & report.



3. Monitor and evaluate the implementation status of the National Antimicrobial Consumption and Antimicrobial Use surveillance.

Formation of sub-committee/ working committee to work closely with special priorities on Antimicrobial Containment issues.

### 2.3 ToR of AMR Cell of DGDA

1. To conduct AMC/U surveillance in Bangladesh.

2. Periodic review and approval of the National Antimicrobial Consumption and Antimicrobial Use survey activity & report.

3. Coordinate and implement AMR Awareness.

4. On behalf of DGDA this cell will work on AMR related activities.

### 2.4 Relevant Stakeholders

The registered manufacturers of antimicrobial drugs in Bangladesh, the importers and the Government agencies who are involve in

donation receive (antimicrobial drugs) are the main key stakeholders.

### 2.5 Timeline for the data submission and report generation

Every year in January DGDA will issue an official letter to the antimicrobial drug manufacturer/importers/other govt. agencies to submit the distribution/import/donation data of last year within 31th January.

The report will be generated within 30th April. The reporting frequency and timeline can be changed with prior permission from the “Task Force to Monitor AMC/AMU Surveillance in Bangladesh”.



# Methodology

# 3.0 Methodology

The Directorate General of Drug Administration, as national regulatory authority, is responsible ensuring the quality, safety and efficacy of medical products in Bangladesh. In Bangladesh, as per the Drugs (Control) Ordinance, 1982 section 5 (1) “ No medicine of any kind shall be manufactured for sale or be

imported, distributed or sold unless it is registered with the licencing authority.” For setting up a surveillance system on antimicrobial consumption and for standardized data collection at the national context, DGDA will follow the following WHO’s guidance documents as common technical basis-

1. WHO methodology for a global programme on surveillance of antimicrobial consumption.
2. GLASS Methodology for surveillance of national antimicrobial consumption.
3. GLASS Manual on the management of antimicrobial consumption data

## 3.1 ATC/DDD System

### ATC Classification system

The Anatomical Therapeutic Chemical (ATC) classification system is the most commonly used method for aggregation of medicines data and allows flexibility in reporting by medicine or groups of medicines.

In this system, the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.

<b>Level 1</b>	indicates the anatomical main group and consists of one letter. There are 14 main groups. The group most relevant to work on antimicrobials is group J Anti-infectives for systemic use. However, there are some examples of antimicrobials classified in other main groups, e.g. antibiotics used as intestinal anti-infectives are in ATC main group A Alimentary tract and metabolism, while some oral and rectal anti-protozoal agents are in ATC main group P Anti-parasitic products, insecticides and repellants.
<b>Level 2</b>	pharmacological/therapeutic subgroups, e.g. J01 is Antibacterials for systemic use, J02 Antimycotics and J04 Antimycobacterials.
<b>Level 3</b>	chemical/pharmacological subgroups, e.g. J01C is Beta-lactam antibacterials, penicillins
<b>Level 4</b>	pharmacological subgroup, e.g. J01CA is Penicillins with extended spectrum
<b>Level 5</b>	chemical substance, e.g. J01CA01 is ampicillin and J01CA04 is amoxicillin.

### 3.2 Measurement Units : Defined Daily Dose (DDD)

The most commonly used measurement statistic is the number of Defined Daily Doses (DDDs). The Defined Daily Dose (DDD) is the assumed average maintenance dose per day for a medicine used for its main indication in adults. A DDD is only assigned for drugs that already have an ATC code. The DDD, however, is only a technical unit of use and does not necessarily reflect the recommended or average prescribed dose.

The DDDs for the anti-infectives are as a main rule based on the use in infections of moderate severity. However, some anti-infectives are only used in severe infections and their DDDs are assigned accordingly.

There are no separate DDDs for children which makes the DDD estimates for pediatric formulations more difficult to interpret.

The numbers of DDDs is calculated as follows:

$$\text{Number of DDDs} = \frac{\text{Total grams used}}{\text{DDD value in grams}}$$

Where the total grams of the medicine used is determined by summing the amounts of active ingredient across the various formulations (different strengths of tablets or capsules, syrup formulations, injections etc.) and pack sizes.

The numbers of DDDs provides a measure of extent of use, however for comparative purposes these data are usually adjusted for population size or population group, depending on the medicines of interest and the level of data disaggregation that is possible.

For most antimicrobials, the DDDs/1000 inhabitants/day (DID) will be calculated for the total population including all age and gender groups (if applicable). The possible to stratification of the national estimates are age group, gender, sectors (community and hospital, public and private).

### 3.3 Antimicrobials included in monitoring

Based on the WHO surveillance program, DGDA focuses only on antimicrobials for systemic use excluding the Topical Antimicrobials.

The core set of antimicrobials that are included in the National AMC surveillance in Bangladesh are:

<b>Antibacterials</b>	J01
<b>Antibiotics for alimentary tract</b>	A07AA
<b>Nitroimidazole derivatives for protozoal diseases</b>	P01AB

In consideration of optimal list of Antimicrobials available in Bangladesh, National AMC

surveillance will include the registered molecules of the following categories -

<b>Antifungals</b>	J02
<b>Antimycotics</b>	D01BA
<b>Antivirals</b>	J05
<b>Antimycobacterials for treatment of Tuberculosis</b>	J04A
<b>Antimalarials</b>	P01B

### 3.4 Different level of health care Sector

National AMC surveillance center as well as AMR cell of DGDA will explore the mechanism of stratifying the National level data based on

WHO recommended the health care sector (Public & Private) and two health care level (hospital & Community).

#### Combinations of health care sectors and levels

LEVEL / SECTOR	PUBLIC	PRIVATE	GLOBAL
Community			
Hospital			
Total			


### 3.5 (a) Common Data Source of AMC surveillance based on the medicine value chain

As per GLASS Methodology for surveillance of national antimicrobial consumption Guideline potential sources of information on AMC Information on the AMC can be obtained from five levels of the value chain of medicines as shown in Fig. 3.

The levels are:

- procurement and supply
- distribution
- prescribing
- dispensing
- patient use.

**Fig: 3 Value Chain of Medicine**



**3.5 (b) Determination of Data Source in the context of Bangladesh AMC Surveillance**

To conduct the AMC surveillance in Bangladesh the common source will be (1) procurement and supply (import and donation) and (2) distribution (locally manufactured and distributed).

Compared to the production data, the distribution data\* provides the closest estimation of national consumption.

**Data Collection Source:**

1. Local manufacturers.
2. DGDA NOC section.
3. DGDA Indent section.
4. Importers and other government agencies.

\*distribution data = products leaving the central warehouse of the concerned manufacturer for further distribution and consumption.

**3.6 The framework for estimating consumption in the Context of Bangladesh**

- The General estimate of the national Antimicrobial Consumption in Bangladesh are-
- Sale in the Domestic Market + Import (finished product) + Donation Therefore, only the sale in the domestic market and antimicrobials distributed through different programs are consumed by the inhabitants of the country. For convenience and accuracy, the

quantity of pharmaceutical products leaving the factory to be distributed within the country for domestic consumption will be collected. If there is no import or no donation of the Antimicrobial Products then the value zero “o” will be incorporated.

- Finally, the proxy estimate of the National Consumption in Bangladesh is-

**Products leaving the factory for distribution in the Domestic Market + Import (finished product) + Donation**



# Data Collection

# 4.0 Data Collection

According to the WHO- “GLASS Methodology for surveillance of national antimicrobial

consumption”, the general elements of data collection for AMC are-

<b>Antimicrobial consumption data</b>	<ul style="list-style-type: none"> <li>• Product level data</li> <li>• Consumed packages at product level (aggregated packages)</li> <li>• May be stratified by health care levels and sectors</li> </ul>
<b>Denominator data</b>	<ul style="list-style-type: none"> <li>• Population under surveillance to which data apply</li> <li>• May be stratified by health care sectors</li> </ul>
<b>Contextual information related to antimicrobial consumption</b>	<ul style="list-style-type: none"> <li>• Data source informations; for example, national reference data (total) or health care sector (community or hospital)</li> <li>• Which antimicrobials are included in surveillance</li> <li>• Specific exclusions of health care institutions (e.g nursing homes, day care centres, psychiatric facilities and private sector)</li> </ul>

## 4.1 Steps by step the data collection Procedures

### Step-1: Updating the Antimicrobial products in prescribed excel format

- For the collection of AMC surveillance data, DGDA-AMR cell will update the product list and the manufacturer list every year based on the relevant data of AM products. (Until web-based AMC data reporting system developed)
- The distribution data for AMC surveillance will be updated at the product level (proprietary and generic products) and comprise information on the active substance(s) of the product, route of administration, strength per unit, number of units per package and total number of packages consumed.
- The procurement and supply (import and

donation) data will be collected from the importer and the government agencies comprise information on the active substance(s) of the product, route of administration, strength per unit, number of units per package and total number of packages consumed.

- Data collection will be facilitated by means of a standard Excel template with functions to calculate volume and consumption for each product.
- Appropriate coding (ATC5) at WHO AMC template will also be populated and/or updated based on Product ID.

### Step-2: Communication with the stakeholders

- DGDA will issue an official letter to the manufacturers & relevant stakeholders to provide the antimicrobial distribution data

(or donation or import if any). (Annexure -2: Letter Format of AMC Surveillance). If required, a reminder letter will be issued.



- Data will be collected once in a year.
- Export data will not be collected. The antimicrobials available only for veterinary use will only be included when it is necessary.
- DGDA will provide an Excel sheet for each manufacturer/stakeholders to provide the data. This EXCEL sheet will be formulated/updated by using DGDA website database (Annexure-3:

Template of Data Collection (in EXCEL sheet) for AMC Surveillance).

- In case of development of Web based AMC data reporting system, the communication with the stakeholders will be facilitated by the IT system.
- Proper monitoring and overall coordination of data collection will be conducted by the AMR cell in collaboration with WHO.

### Step-3: Preliminary validation and re-communication (if required)

- The received data will be thoroughly evaluated for ensuring the harmonized “quantity based on unit” provided by the stakeholder/manufacturer.
- In case of any confusion arise during checking, AMR cell will communicate with the

concerned stakeholder to confirm/correct the data or triangulate with other sources of data like IQVIA.

- The collection of relevant contextual information will also be ensured.

### Step-4: Compilation of data and populating WHO AMC template

- The Compiled data will be populated to the latest WHO AMC template.

## 4.2 Template for Data Collection

The WHO AMC Excel template has multiple worksheets for entering:

- data for the main ATC groups and health care sectors and levels per year

- population per year
- consumption data at product level including:
  - the list of products
  - the consumed number of packages per year, and the health care sectors and levels.

### 4.3 Structure of template

---

<b>Macro</b>	These are embedded routines to assist in data checking and export.
<b>Data Availability</b>	for each category of medicine (A07AA, D01BA, J01, J02, J04, J05, P01AB, N04BB) indicate whether the data represent the total, community or hospital consumption
<b>Product Data</b>	the key worksheet for data. A separate guidance document is available to provide step-by-step advice on completing this worksheet.
<b>Population Data</b>	for each category of medicine (A07AA, D01BA, J01, J02, J04, J05, P01AB, N04BB) indicate population to which the given consumption data apply
<b>ATC</b>	list of medicines being monitored, with ATC code and ATC level.
<b>DDD</b>	the DDD assigned by the WHO Collaborating Centre with units of measurement (gram, mg, MU)
<b>DDD combination</b>	provides a list of combination medicines that have an approved DDD or approved 'unit dose' measurement
<b>Conversion</b>	a table of conversion factors from MU to grams (See Annex 4)
<b>Units</b>	a description of the units used (See Annex 5)
<b>Salts</b>	the specification of salts is only required for hexamine (hippurate or mandelate) and where erythromycin data relate to the ethylsuccinate salt.
<b>RoAs</b>	routes of administration (oral, parenteral, rectal, inhalation powder, inhalation solution). (See Annex 6)

---



Variables

# 5.0 Variables

## Variables for antimicrobial medicines register

DGDA has a database of registered drugs in their website ([www.dgda.gov.bd](http://www.dgda.gov.bd)) which are publically available. Using this database a list of antimicrobial drugs can be created. The following product-level variables are being

used to conduct this AMC surveillance. Data of imported and donated antimicrobial drugs will be collected from the importers or Government agencies like- National TB program etc using these same variables.

**Table 2: Product-level data variables for the antimicrobial register (for local production, import and donation)**

<b>COUNTRY</b>	Based on ISO 3166 alpha-3 country codes
<b>PRODUCT_ID</b>	Unique identifier of the medicinal product package (MPP)
<b>LABEL</b>	Medicinal product package label
<b>PACKSIZE</b>	Size of the package
<b>PACKSIZE_UNIT</b>	Pack size unit of measurement
<b>PAEDIATRICS_PRODUCT *</b>	Is it a paediatric medicine product
<b>FORM*</b>	Pharmaceutical formulation type
<b>ROUTE_ADMIN</b>	Route of administration
<b>STRENGTH</b>	Quantity of the main ingredient of each item
<b>STRENGTH_UNIT</b>	Unit measurement of strength
<b>INBASQ</b>	Basic ingredient quantity
<b>INBASQ_UNIT</b>	Unit measurement of the basic ingredient quantity
<b>ATC5</b>	WHO ATC code at substance level (ATC5-level)
<b>SALT *</b>	Salt of the active substance (hexamine, erythromycin only)
<b>COMBINATION</b>	The WHO CC has defined DDD for combined products
<b>PRODUCT_NAME *</b>	Medicinal product name
<b>INGREDIENTS *</b>	Ingredient name: e.g. amoxicillin and enzyme inhibitor.
<b>PRODUCT_ORIGIN *</b>	The product can be import, donation or locally produced.

**Table 2: Product-level data variables for the antimicrobial register**

<b>MANUFACTURER_COUNTRY</b>	The country of the manufacturer of the product.
<b>MANUFACTURER *</b>	Name of manufacturer
<b>GENERIC*</b>	Is the product a generic?
<b>CONV_FACTOR (macro)</b>	Transform strength expressed in IU into G.
<b>WHO_DDD (macro)</b>	The DDD defined by the WHO CC for the ATC code
<b>WHO_DDD_UNIT (macro)</b>	Unit measurement of the WHO DDD (MG, G, IU, MU, UD)
<b>DPP (macro)</b>	DDD Per Package

### 5.1 Incorporation of data into WHO\_AMC\_Template\_latest version

Steps involved in entering data into WHO_AMC_Template	data collected and reported
<ul style="list-style-type: none"> <li>• Enter the product information</li> <li>• Enter the population information</li> <li>• Enter the information about availability of</li> </ul>	<ul style="list-style-type: none"> <li>• Run the Macros to validate entered data and calculate DDD</li> <li>• Run the Macros to export data into the required format for GLASS submission</li> </ul>

### 5.2 Population Data- Denominator data

ISO Country code (Alpha-3 Code): BGD Year: Sector: GLO	Total Population: UN population data will be collected from the following website: <a href="https://population.un.org/wpp/Download/Standard/Population/">https://population.un.org/wpp/Download/Standard/Population/</a>
--	---

### 5.3 Product Data

<ul style="list-style-type: none"> <li>• Mandatory data will be required to be inserted (blue color cells), Like: COUNTRY, PRODUCT_ID, LABEL, PACKSIZE, PACKSIZE_UNIT, ROUTE_ADMIN, STRENGTH, STRENGTH_UNIT, INBASQ, INBASQ_UNIT, ATC5, SALT, COMBINATION</li> </ul>	<ul style="list-style-type: none"> <li>• Optional data will be used to collect/gather additional information e.g. generics, marketing authorization holder, country of origin, etc.</li> </ul>
--	--

### 5.4 Validation of data

AMR cell will check the completeness and accuracy of the provided data. The relevant ATC codes and formats will be checked in collaboration with relevant experts/members from task force to monitor AMC/AMU surveillance in Bangladesh.	If required, the obtained data will be compared with IQVIA data to get the essence of trend. AMR cell members in collaboration with WHO and task force members will ensure that the data is validated and triangulated with different sources of data.
--	--



Reporting metrics

## 6.0 Reporting metrics

The standard reporting metric for national estimates is DDDs/1000inhabitants/day (DID). The data collection template requires entry of numbers of packages for each product included in the register. These packages may be summed to give a total number of packages consumed. This will provide a crude estimate of the number of courses of treatment with antimicrobials used per year and is based on the assumption that one package = one course of

treatment. This measure needs to be interpreted carefully. In some settings, a package of oral medicine will represent a course of treatment. In other settings, patients may buy small numbers of tablets or capsules or dispensing is from large containers of the medicine, in which case a package will have very little meaning. A package is not likely to be a good guide to a course of treatment with an injectable antimicrobial.

### 6.1 Data Analysis using the exported AMC Excel files

The export excel file from WHO AMC template will be used for further analysis of DDDs/DIDs. The “GLASS Manual on the management of antimicrobial consumption data” will be followed for step-by-step analysis of the AMC data.

Absolute or relative consumption can be presented as- DDD per 1000 inhabitants per day in total and by:

- by pharmacological subgroup
- by route of administration (mainly oral and parenteral)
- by AWaRe categories (Access, Watch and Reserve)
- by generation
- by geographical region
- by sector (hospital/community, private/public)
- list of most frequently used substances (comprising 75% or 90% of total consumption)


### 6.2 Report Generation

The macros of the WHO AMC Template will check the validity of the entered data and finally the consumption data will be exported as Defined Daily Doses (DDD) per 1000 inhabitants per day.

The Final report will consist the following results:

- a) Total Consumption of Antimicrobials.** Antimicrobial consumption will be expressed in Defined Daily Doses (DDD) per 1000 inhabitants per day.

**Output example: National antimicrobial consumption in Bangladesh, 2019-2020**




**b) Detail of the Total Consumption of Antimicrobials:**

The list of selected antimicrobials, consumption of which will be studied (in alphabetic order),

ATC Code and their corresponding consumption will be expressed in DDD/1000 inhabitants per day during the study period.


For an example:






c) DID by AWaRe categories:

For an example:



d) DID by pharmacological subgroup



e) DID by route of administration (mainly oral and parenteral)

For an example:

Antimicrobial Drugs	DU 75% (Oral)		DU 75% (Parenteral)	
	2020	2019	2020	2019
azithromycin	7.09	6.18		
ceftriaxone			0.31	0.40
cefixime	3.06	3.59		
metronidazole	2.70	2.20	0.039	0.042
doxycycline	2.15	1.73		
ciprofloxacin	1.60	1.84		
cefuroxime		1.45		
flucloxacillin	1.50	1.41		
amoxicillin	1.41			

f) DID of Other Antimicrobials not Mentioned in AWaRe Categorization

For an example:

AWaRe Category	Consumption of Antimicrobials (DDD per 1000 inhabitants per Day)	
	2019	2020
Access	9.08	10.24
Watch	15.40	14.90
Reserve	0.06	0.06
Others	0.21	0.18


g) DID by sector or geographical region (if required)

i) Pattern of Consumption of Antimicrobials by generation

h) List of most consumed or Drug Utilization 75%/90% (DU75 / DU90)

For an example:

DDD per inhabitant per Day by Generation of Cephalosporins



j) Any other analysis report as appropriate.



Dissemination of data

## 7.0 Dissemination of data

**E**very year AMR cell of DGDA will conduct the AMC surveillance and place the report to the taskforce to monitor AMC/AMU Bangladesh and National Technical Committee/ National Coordination Centre. (Annexure-5: Office order of “AMR Cell” of DGDA).

An expert committee will analyze/evaluate this data. This committee will evaluate the trend of antimicrobial consumption patterns compared with AMR data (collected from IEDCR) and will recommend for decision/policy making. The recommendation of this expert committee will be presented in the Taskforce to monitor AMC/AMU Bangladesh. The Taskforce will finally recommend further required action.

After approval and recommendation of the

Taskforce the following action will be taken:

**a)** Regulatory action/decision of policy making will be taken by DGDA/DGHS/CDC/IEDCR. On the basis of this recommendation if any regulatory action will be taken that will be presented in the next Task Force meeting. The Concerned department/Ministry will monitor the activity.

**(b)** The national focal person of AMC surveillance/ the alternate national focal person of AMC surveillance will report to GLASS AMC and publish at national and international level.

**(c)** The summary report will be published/ reported to GLASS AMC through the GLASS-AMC National Focal or Alternate National Focal.



Conclusion

# 8.0 Conclusion

Tracking antibiotic consumption within a country is an important component of the national action plan of AMR of Bangladesh. It allows for informed decisions on where to focus efforts to reduce unnecessary use and can assist evaluation of initiatives. Information on antibiotic consumption at the national level is valuable when formulating policies, developing

formulary controls, or making decisions on prescribing guidelines or guidelines for prudent use in animals. Consumption data is further useful for benchmarking purposes and comparison between countries/regions/hospitals/-farms. So as a National center for AMC surveillance, DGDA will continue the Antimicrobial Consumption Surveillance every year.

## References

1. GLASS methodology for surveillance of national antimicrobial consumption.
2. Antimicrobial Resistance in the Western Pacific Region: A Review of Surveillance and Health Systems Response.
3. GLASS guide for national surveillance systems for monitoring antimicrobial consumption in hospitals.
4. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
5. Surveillance and monitoring for antimicrobial use and resistance- IACG discussion paper.
6. WHO Report on Surveillance of Antibiotic Consumption: 2016 – 2018 Early implementation.
7. GLASS Manual on the management of antimicrobial consumption data.



Definition



# Definition

## Antimicrobials

Antimicrobials – including antibiotics, antivirals, antifungals and antiparasitics – are medicines

used to prevent and treat infections in humans, animals and plants.

## Antimicrobial Resistance (AMR)

Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines making infections harder to treat and increasing the risk of disease spread, severe illness and death.

As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat.

## Antimicrobial stewardship

The use of co-ordinated interventions to improve and measure the use of antimicrobials by promoting optimal drug regimen, dose,

duration and route are key components of a multi-faceted approach to prevent antimicrobial resistance and limit selection of resistant pathogens.

## AWaRe Classification

The AWaRe Classification of antibiotics was developed in 2017 by the WHO Expert Committee on Selection and Use of Essential Medicines as a tool to support antibiotic stewardship efforts at local, national and global levels.

The AWaRe Classification classifies Antibiotics into three groups, Access, Watch and Reserve, taking into account the impact of different antibiotics and antibiotic classes on antimicrobial resistance, to emphasize the importance of their appropriate use.

## Broad-spectrum antibiotics

These are effective against a wide range of bacteria. For example, meropenem is a broad-spectrum antibacterial.

### Carbapenems

Carbapenems are broad-spectrum antibiotics, often used as the last line of treatment for hard to treat human infections caused by Gram-negative bacteria.

### Carbapenemases

These are enzymes produced by bacteria which destroy carbapenems and other beta-lactam antibiotics.

### Cephalosporins

Types of broad-spectrum antibiotics.

### Cephalosporins – third-generation

Cephalosporins like cefotaxime and cefixime are particularly active against Gram-negative bacteria.

### Generic (name)

The accepted or official nonproprietary name (not a chemical formula or a brand) by which a medicine is identified.

### Gram-negative bacteria

Those bacteria that do not retain crystal violet dye in the Gram-staining procedure. They can cause many types of infection and include *E. coli* and *Pseudomonas aeruginosa*.

### Gram-positive bacteria

These are bacteria that are stained dark blue or violet in the Gram-staining procedure. They include *Staphylococcus aureus* and *Clostridium difficile*.

### Multi-drug resistant

Resistance to two or more antibiotics from

different classes.

### 'One-Health' approach

Describes a coordinated, collaborative, multi-disciplinary and cross-sectoral work at local, national, and global levels to attain optimal health for people, animals and the environment.

### Pathogen

An infectious agent (bug or germ), a microorganism such as a virus, bacterium, or fungus that causes disease in its host.

## Consumption data

Consumption data refer to estimates derived from aggregated data sources such as import or wholesaler data where there is no information available on the patients who are receiving the medicines or why the antimicrobials are being used. These data sources provide a

proxy estimate of use of antimicrobials.

Consumption data may be presented as total consumption for a country or may be disaggregated by setting (community or hospital; public or private sectors).

## Antimicrobial use data

Antimicrobial use data refer to estimates derived from patient-level data. These data may allow disaggregation of data based on patient characteristics (gender, age), or indication for which the medicine is being used. Depending

on the source of information, it may be possible to determine the patients' symptoms, physician diagnoses and medications ordered. This will facilitate assessment of clinical practice against agreed protocols and treatment guidelines.

## Antimicrobial Consumption (AMC)

Antimicrobial consumption (AMC) is measured in defined daily dose (DDD), which is the

assumed average maintenance dose per day for a drug used for its main indication in adults.

## AMC Surveillance

AMC data are estimates derived from aggregated data sources (ranging from macro-level, such as imports, donation, distribution and sales, to micro-level, such as data on prescriptions, dispensing and insurance). Consumption indicates the types and quantities of antimicrobials used in a specific setting over a specific period.

In order to obtain a thorough and comprehensive picture of antimicrobial resistance and to be able to identify areas in which actions are needed, surveillance data are essential. This includes data on antimicrobial resistance and also antimicrobial consumption. Surveillance systems should provide data that can be easily compared, exchanged or used locally, nationally and globally.

**AWaRe Classification 2021**

Access	Watch	Reserve
Amikacin	Arbekacin	Aztreonam
Amoxicillin	Aspoxicillin	Carumonam
Amoxicillin/clavulanic-acid	Azithromycin	Cefiderocol
Ampicillin	Azlocillin	Ceftaroline-fosamil
Ampicillin/sulbactam	Bekanamycin	Ceftazidime/avibactam
Azidocillin	Biapenem	Ceftobiprole-medocaril
Bacampicillin	Carbenicillin	Ceftolozane/tazobactam
Benzathine-benzylpenicillin	Carindacillin	Colistin_IV
Benzylpenicillin	Cefaclor	Colistin_oral
Brodimoprim	Cefamandole	Dalbavancin
Cefacetrile	Cefbuperazone	Dalfopristin/quinupristin
Cefadroxil	Cefcapene-pivoxil	Daptomycin
Cefalexin	Cefdinir	Eravacycline
Cefaloridine	Cefditoren-pivoxil	Faropenem
Cefalotin	Cefepime	Fosfomycin_IV
Cefapirin	Cefetamet-pivoxil	Iclaprim
Cefatrizine	Cefixime	Imipenem/cilastatin/rele-
Cefazedone	Cefmenoxime	bactam
Cefazolin	Cefmetazole	Lefamulin
Cefradine	Cefminox	Linezolid
Cefroxadine	Cefodizime	Meropenem/vaborbactam
Ceftezole	Cefonicid	Minocycline_IV
Chloramphenicol	Cefoperazone	Omadacycline
Clindamycin	Ceforanide	Oritavancin
Clometocillin	Cefoselis	Plazomicin
Cloxacillin	Cefotaxime	Polymyxin-B_IV
Dicloxacillin	Cefotetan	Polymyxin-B_oral
Doxycycline	Cefotiam	Tedizolid
Epicillin	Cefoxitin	Telavancin
Flucloxacillin	Cefozopran	Tigecycline
Furazidin	Cefpiramide	
Gentamicin	Cefpirome	
Hetacillin	Cefpodoxime-proxetil	
Mecillinam	Cefprozil	
Metampicillin	Cefsulodin	

**AWaRe Classification 2021**

Access	Watch
Meticillin	Ceftazidime
Metronidazole_IV	Cefteram-pivoxil
Metronidazole_oral	Ceftibuten
Nafcillin	Ceftizoxime
Nifurtoinol	Ceftriaxone
Nitrofurantoin	Cefuroxime
Ornidazole_IV	Chlortetracycline
Ornidazole_oral	Cinoxacin
Oxacillin	Ciprofloxacin
Penamecillin	Clarithromycin
Phenoxymethylpenicillin	Clofoctol
Pivampicillin	Clomocycline
Pivmecillinam	Delafloxacin
Procaine-benzylpenicillin	Demeclocycline
Propicillin	Dibekacin
Secnidazole	Dirithromycin
Spectinomycin	Doripenem
Sulbactam	Enoxacin
Sulfadiazine	Ertapenem
Sulfadiazine/tetroxoprim	Erythromycin
Sulfadiazine/trimethoprim	Fidaxomicin
Sulfadimethoxine	Fleroxacin
Sulfadimidine	Flomoxef
Sulfadimidine/trimethoprim	Flumequine
Sulfafurazole	Flurithromycin
Sulfaisodimidine	Fosfomicin_oral
Sulfalene	Fusidic-acid
Sulfamazone	Garenoxacin
Sulfamerazine	Gatifloxacin
Sulfamerazine/trimethoprim	Gemifloxacin
Sulfamethizole	Grepafoxacin
Sulfamethoxazole	Imipenem/cilastatin
Sulfamethoxazole/trimetho- prim	Isepamicin
Sulfamethoxypyridazine	Josamycin
	Kanamycin_IV

## AWaRe Classification 2021

Access	Watch
Sulfametomidine	Kanamycin_oral
Sulfametoxydiazine	Lascufloxacin
Sulfametrole/trimethoprim	Latamoxef
Sulfamoxole	Levofloxacin
Sulfamoxole/trimethoprim	Levonadifloxacin
Sulfanilamide	Lincomycin
Sulfaperin	Lomefloxacin
Sulfaphenazole	Loracarbef
Sulfapyridine	Lymecycline
Sulfathiazole	Meropenem
Sulfathiourea	Metacycline
Sultamicillin	Mezlocillin
Talampicillin	Micronomicin
Tetracycline	Midecamycin
Thiamphenicol	Minocycline_oral
Tinidazole_IV	Miocamycin
Tinidazole_oral	Moxifloxacin
Trimethoprim	Nemonoxacin
	Neomycin_IV
	Neomycin_oral
	Netilmicin
	Norfloxacin
	Ofloxacin
	Oleandomycin
	Oxolinic-acid
	Oxytetracycline
	Panipenem
	Pazufloxacin
	Pefloxacin
	Penimepicycline
	Pheneticillin
	Pipemidic-acid
	Piperacillin
	Piperacillin/tazobactam
	Piromidic-acid

Watch
Pristinamycin
Prulifloxacin
Ribostamycin
Rifabutin
Rifampicin
Rifamycin_IV
Rifamycin_oral
Rifaximin
Rokitamycin
Rolitetracycline
Rosoxacin
Roxithromycin
Rufloxacin
Sarecycline
Sisomicin
Sitafloxacin
Solithromycin
Sparfloxacin
Spiramycin
Streptoduocin
Streptomycin_IV
Streptomycin_oral
Sulbenicillin
Tazobactam
Tebipenem
Teicoplanin
Telithromycin
Temafloxacin
Temocillin
Ticarcillin
Tobramycin
Tosufloxacin
Troleandomycin
Trovafloxacin
Vancomycin_IV
Vancomycin_oral



## Annexes



Government of the People's Republic of Bangladesh  
Ministry of Health and Family Welfare  
Health Services Division  
Drug Administration-1 Section  
...www.hsd.gov.bd



Record Number: 45.00.0000.182.82.001.21.48 Date: 2/2/2022  
Recipients: Dr. Bardan Jung Rana, WHO Representative  
World Health Organization, Country Office for Bangladesh

**Subject: Nomination of the National Focal Point and Alternative National Focal point for WHO Global Antimicrobial Resistance Surveillance System (GLASS-AMC) reporting.**

Ref: 1. WHO South-East Asia memo no- D7/48/1, dated: 10 June, 2019  
2. DGDA memo no: DGDA/AMR/2020/90, dated: 27/01/2022.

As per the above mentioned subject, we are happy to know that WHO inviting Bangladesh to enroll in the antimicrobial consumption component of WHO Global Antimicrobial Resistance Surveillance System (GLASS-AMC).

02. In response to the letter of WHO South-East Asia memo no- D7/48/1, date: 10 June, 2019 I am nominating below persons as GLASS-AMC National Focal Point and Alternate National Focal Point as per instruction.

**National Center for AMC surveillance:**

Name of Institution: Directorate General of Drug Administration

Address: Aushadh Vaban, Mohakhali, Dhaka-1212.

Institutional E-mail: dgda.gov@gmail.com Institution phone: +880222280803

**National Focal Point(s) for AMC Surveillance:**

• **National Focal Point:**

- Surname: Salahuddin First Name: Md Title: Mr.
- Position: Director (cc)
- Institution: Directorate General of Drug Administration
- E-mail: salahuddin733@yahoo.com
- Telephone: Work: N/A Mobile: +8801711242493

• **Alternate National Focal Point:**

- Surname: Yesmin First Name: S. M. Sabrina Title: Ms.
- Position: Assistant Director
- Institution: Directorate General of Drug Administration
- E-mail: sabrinayesmin22@gmail.com
- Telephone: Work: N/A Mobile: +8801722903474

03. We hope that Bangladesh will work together with WHO regarding capacity building, access to implementation tools and surveillance of Antimicrobial Consumption at National level.

**Attachment:** Annex-'A'



Yours faithfully,



2-2-2022

Muhammad Mustafizur  
Rahman  
Assistant Secretary  
Phone: 9545462 (Office)  
Email: drugad1@hsd.gov.bd

Record Number:

Date: 2/2/2022

45.00.0000.182.82.001.21.48/1(6)

Copy for kind information and necessary action (Not according to seniority):

- 1) Director General, Directorate General of Drug Administration, Mohakhali, Dhaka.
- 2) Additional Secretary (Drug Administration), Health Service Division, Dhaka.
- 3) PS to Senior Secretary, Health Services Division, Ministry of Health and Family Welfare, Dhaka.
- 4) Systems Analyst, Computer Cell, Ministry of Health and Family Welfare, Dhaka (with a request to upload this notification on the Ministry's website)
- 5) Dr. Mohamed Ramzy Ismail, Technical Officer-EDM, WHO Country Office for Bangladesh, House: 1/A, Road-8, Gulshan-1, Dhaka.
- 6) Office Copy.



2-2-2022

Muhammad Mustafizur  
Rahman  
Assistant Secretary

## Annexure-2

Government of the People's Republic of Bangladesh  
Directorate General of Drug Administration  
Aushodh Vaban  
Mohakhali,  
Dhaka-1212, Bangladesh

Memo No: DGDA/AMR-1/2020/

Date: .....

To: M/S.....

**Subject: To provide distribution /import/donation statement of antibiotic for Antimicrobial Consumption Surveillance (AMC) for the Year .....**

According to the above subject this is to inform you that Antimicrobial use is one of the main drivers of antimicrobial resistance (AMR); hence, surveillance and optimal use of antimicrobial medicines are among the key strategies to combat AMR. There is an urgent need for mechanisms to monitor antimicrobial consumption (AMC).

In this regard you are requested to submit your antibiotic locally distribution/import/donation (excluding export data) statement (for the Year .....) as per the provided XL-sheet to your e-mail.

Please send the antibiotic distribution/import/donation statement within ..... to the following e-mail:.....

**Attachments:** 1. XL-sheet (send by e-mail).  
2. Product List.

Signature  
Director General  
Directorate General of Drug  
Administration  
Cont: 02222280803  
e-mail: dgda.gov@gmail.com

Memo No: DGDA/AMR-1/2020/

Date: .....

**Attention:**

1. Chairperson, the task force to monitor AMC/AMU Bangladesh.
2. Focal/ Alternet focal of AMC surveillance in Bangladesh.
3. Technical Officer-Essential Drugs and Medicines, WHO, Bangladesh country office.
4. Others (if required).

Director General  
Directorate General of Drug Administration

### Annexure-3 : Template of Data Collection (in EXCEL sheet) for AMC Surveillance

The template of data collection (in EXCEL sheet) for AMC Surveillance will be contained the following variables:

Name of the Manufacturer

Production Unit (if any)

Brand Name

Generic Name

DAR

Strength

Dosage Description

Route of admin


Pack Size

Pack Size (unit)

Year    Jan-Jun  
          (pcs)

          Jul-Dec  
          (pcs)

**Annexure-4 : Process flow of AMC surveillance in Bangladesh:**



Government of the People's Republic of Bangladesh  
Directorate General of Drug Administration  
Aushodh Vaban  
Mohakhali,  
Dhaka-1212, Bangladesh



Memo No: DGDA/AMR-1/2020/3834

Date: 15.10.2022

**Subject: Formation of DGDA AMR Cell.**

According to the above subject DGDA AMR Cell is formulated with the following officers.

1. Director General, Directorate General of Drug Administration.
2. Mr. Md Salahuddin, Director (cc), DGDA.
3. Mr. Razibul Habib, Assistant Director, DGDA.
4. Ms. S. M. Sabrina Yesmin, Assistant Director, DGDA.
5. Mr. A T M Golam Kibria Khan, Assistant Director, DGDA.

**TOR of this cell:**

1. To conduct AMC/U surveillance in Bangladesh.
2. Implementation of National Action Plan and Strategic Plan of AMR (DGDA part).
3. Coordinate and implement AMR Awareness.
4. On behalf of DGDA this cell will work on AMR related activities.

  
Major General Md Mahubur Rahman  
Director General

Directorate General of Drug Administration  
Cont: 02222280803

e-mail: [dgda.gov@gmail.com](mailto:dgda.gov@gmail.com)

**Distribution: (Not according to the seniority)**

1. Mr. Md Salahuddin, Deputy Director, DGDA.
2. Mr. Razibul Habib, Assistant Director, DGDA.
3. Ms. S. M. Sabrina Yesmin, Assistant Director, DGDA.
4. Mr. A T M Golam Kibria Khan, Assistant Director, DGDA.
5. Assistant Director, Admin, DGDA.
6. PA to DG, Directorate General of Drug Administration.



Directorate General of Drug Administration  
Mohakhali, Dhaka-1212  
Ministry of Health and Family Welfare, Bangladesh.